A Study to Assess the Mass Balance Recovery, Pharmacokinetics, Metabolite Profile and Metabolite Identification of [14C]AZD4831

Model scores of the 29,894 trials active now.

Model score 5% for any early termination, 0% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 7% of the time (318 trials).

Finished trial that started in 2015 or later: the model never saw it during training.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2020-08-06. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Accepts healthy volunteers: Yes (lowers risk) · Who can join
• Wording of the registration (title, summary, criteria) (lowers risk) · Wording Phrases that raised it: heartsubjects withfailurecellradiation
  Phrases that lowered it: healthyvolunteersalcoholadministrationsingle
• Phase: 1 (lowers risk) · Design
• Sponsor's past trials: 1611 (raises risk) · Sponsor's track record
• Design: single group (raises risk) · Design
• Trials the sponsor started in the prior 2 years: 126 (lowers risk) · Sponsor's track record
• Sponsor's past termination rate: 8.1% (raises risk) · Sponsor's track record
• Has a data monitoring committee: No (lowers risk) · Design
• Sponsor type: industry (lowers risk) · Sponsor's track record
• Primary purpose: treatment (raises risk) · Design
• Drug's FAERS reports with a death: no FAERS history (raises risk) · Drug's FDA history
• Disease area, cancer: No (lowers risk) · Disease area
• Minimum age: 18 (raises risk) · Who can join
• Blinding: none (lowers risk) · Design
• Drug's FAERS reports marked serious: no FAERS history (raises risk) · Drug's FDA history
• Maximum age: 65 (lowers risk) · Who can join
• Responsible party: sponsor (lowers risk) · Design
• Disease area, psychiatry: No (lowers risk) · Disease area
• Collaborators: 1 (raises risk) · Design

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Study Evaluating the Pharmacokinetic and Mass Balance of Single Dose [14C] AZD5718 in Volunteers NCT03948451 · started 2019 · scored riskier than 4% of active trials completed
• A Study to Assess the Rel Bioavailability, Food Effect and Absolute Bioavailability on the Pharmacokinetics of AZD9833 NCT04546347 · started 2020 · scored riskier than 3% of active trials completed
• An ADME Study of [14C]AZD0780 in Healthy Male Subjects NCT05817461 · started 2023 · scored riskier than 4% of active trials completed
• Absolute Bioavailability and ADME Study of [14C]AZD9977 in Healthy Male Subjects NCT04686591 · started 2020 · scored riskier than 1% of active trials completed
• An ADME Study of [14C]AZD4604 and the Absolute Bioavailability of AZD4604 NCT06157255 · started 2024 · scored riskier than 5% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.